Shanghai Aladdin Biochemical Technology (SH:688179) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-04-23 01:19Investment Overview - Shanghai Aladdin Biochemical Technology Co., Ltd. plans to invest in Shanghai Yamei Biopharmaceutical Technology Co., Ltd. through capital increase and share acquisition, with a total investment of 41.17 million RMB [2][5][19] - The investment will occur in two phases: first, a capital increase of 24.7 million RMB at a valuation of 140 million RMB to acquire 15% equity; second, a share transfer of 10% equity from existing shareholders at a valuation of 164.7 million RMB for 16.47 million RMB [2][19] Company Profile - Shanghai Yamei Biopharmaceutical Technology Co., Ltd. specializes in the research and production of life science research tools, including antibodies, protein reagents, and cell biology products, with a unique advantage in protein immunoblotting solutions [5][18] - The company aims to provide a comprehensive solution for biological experiments, complementing Aladdin's existing product lines in antibodies, proteins, and biochemical reagents [5][18][27] Transaction Details - The total investment of 41.17 million RMB will be funded from the company's own resources, and the transaction does not constitute a major asset restructuring or related party transaction [3][25][26] - The investment has been approved by the company's general manager's office and does not require further approval from the board of directors or shareholders [3][7][9] Financial Metrics - The investment's price-to-earnings ratio is calculated at 14.10 times based on the projected net profit for 2024 [19] - After the investment, the company will hold 25% of Yamei Biopharmaceutical's equity [15][19] Governance Structure - Following the investment, the governance structure of Yamei Biopharmaceutical will include a board of directors with three members, where Aladdin can appoint one director and the founder can appoint two [24]